Robert Wilson, MD
Family Medicine · Lowell, ARNPI 1922041326
Payments from drug & device makers
Across 123 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$414
- AstraZeneca$291
- Novo Nordisk$245
- Pfizer$225
- Lilly USA, LLC$199
- Amgen$144
- plus $639 from 17 others
What the payments were for
- Food & beverage$2,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $414 |
| AstraZeneca | 14 | $291 |
| Novo Nordisk | 16 | $245 |
| Pfizer | 14 | $225 |
| Lilly USA, LLC | 12 | $199 |
| Amgen | 9 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $123 |
| Phathom Pharmaceuticals, Inc. | 6 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Corium, LLC | 2 | $48 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Gilead | 1 | $26 |
| GSK | 1 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Abbott | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$2,157 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $116,726 |
| OzempicSemaglutide | 95 | $111,355 |
| XareltoRivaroxaban | 106 | $71,085 |
| MounjaroTirzepatide | 34 | $48,244 |
| FarxigaDapagliflozin Propanediol | 40 | $42,839 |
| JardianceEmpagliflozin | 39 | $30,677 |
| CreonLipase/Protease/Amylase | 12 | $27,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,351 |
| JanuviaSitagliptin Phosphate | 24 | $17,956 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $16,921 |
| MyrbetriqMirabegron | 31 | $15,050 |
| LinzessLinaclotide | 26 | $14,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,822 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $9,675 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $116,726172 claims |
| Novo NordiskOzempic | $245 | $111,35595 claims |
| Johnson & JohnsonXarelto | $21 | $71,085106 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $291 | $69,582105 claims |
| Lilly USA, LLCMounjaro | $199 | $48,24434 claims |
| AbbVieCreon, Linzess, Synthroid | $414 | $43,50767 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $26 | $36,12174 claims |
| Boehringer IngelheimJardiance | $36 | $30,67739 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $15,05031 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $5,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Lowell
- Cheryl FultonLowell$15K
- Blake BryantLowell$15K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.